Educational protocol hub
SS-31 / Elamipretide: protocol variants and reconstitution resources
Educational hub for SS-31 / Elamipretide, grouping 3 available protocol variants with links to the exact dosage and reconstitution pages.
What this hub covers
This page groups the available SS-31 / Elamipretide protocol variants so readers can choose the exact vial-size guide without mixing formats.
Reconstitution workflow
Use the linked protocol pages and calculator resources to review concentration, diluent logic and unit conversions for the selected variant.
Research-only context
All information is educational and literature-focused. AllPeptides.eu does not sell peptides and does not provide medical advice.
Available protocol variants
Choose the exact guide you want to view.
SS-31 / Elamipretide
SS-31 / Elamipretide is a mitochondria-targeted tetrapeptide studied for its binding to cardiolipin on the inner mitochondrial membrane. Research sources report subcutaneous administration of 5 mg to 10 mg, once daily, increased gradually.
View protocolSS-31 (Elamipretide)
SS-31 (Elamipretide) targets the inner mitochondrial membrane, stabilizing cardiolipin and improving ATP production. Subcutaneous administration. Research sources report subcutaneous administration of 5 mg to 10 mg, once daily, increased gradually.
View protocolSS-31 (Elamipretide)
SS-31 (Elamipretide) targets the inner mitochondrial membrane, stabilizing cardiolipin. Subcutaneous administration. Research sources report subcutaneous administration of 5 mg to 10 mg, once daily, increased gradually.
View protocolRelated research resources
Internal links that help readers and search engines understand this peptide topic cluster.
References
- Br J Pharmacol (2014) — Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics.
View Source - Circ Heart Fail (2017) — Daubert MA, et al. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide.
View Source - Karaa A et al. J Cachexia Sarcopenia Muscle 2020 — A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.
View Source - Butler J et al. J Card Fail 2020 — Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial.
View Source - Siegel MP et al. Aging Cell 2013 — Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice.
View Source - Campbell MD et al. Free Radic Biol Med 2019 — Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice.
View Source - Szeto HH et al. J Am Soc Nephrol 2011 — Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury.
View Source - Ehlers JP et al. Ophthalmol Sci 2025 — ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.
View Source
Educational and laboratory research information only. AllPeptides.eu does not sell peptides and does not provide medical advice or human-use instructions.